Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
A Monte Carlo simulation demonstrated that 1 g of meropenem (MEM) every 8 h (q8h) (3-h infusion) has a higher target attainment rate against Pseudomonas aeruginosa than either 500 mg of MEM q8h (3-h infusion) or 0.5 g of imipenem-cilastatin (I-C) q6h (1-h infusion). For other pathogens, 500 mg of MEM q8h was equivalent or superior to I-C.
Lomaestro
Ben M
BM
Albany Medical Center Hospital, 43 New Scotland Ave., Albany, NY 12208, USA. lomaesb@mail.amc.edu
Drusano
G L
GL
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000382:microbiology; D015377:Cilastatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage / Q000493:pharmacokinetics; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D009010:Monte Carlo Method; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013845:Thienamycins / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination; D000077731:Meropenem